Bessemer Group Inc. Raises Position in Danaher Corporation $DHR

Bessemer Group Inc. raised its holdings in shares of Danaher Corporation (NYSE:DHR) by 6.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,388,962 shares of the conglomerate’s stock after acquiring an additional 146,725 shares during the quarter. Danaher makes up 0.7% of Bessemer Group Inc.’s portfolio, making the stock its 24th largest holding. Bessemer Group Inc. owned 0.34% of Danaher worth $473,636,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tyche Wealth Partners LLC purchased a new stake in Danaher in the third quarter worth about $462,000. Ceredex Value Advisors LLC increased its holdings in Danaher by 1.6% in the 2nd quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after acquiring an additional 3,862 shares in the last quarter. Weitz Investment Management Inc. raised its stake in Danaher by 6.1% during the 2nd quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after acquiring an additional 30,300 shares during the period. Lockheed Martin Investment Management Co. lifted its holdings in Danaher by 49.4% during the third quarter. Lockheed Martin Investment Management Co. now owns 25,340 shares of the conglomerate’s stock valued at $5,024,000 after purchasing an additional 8,380 shares in the last quarter. Finally, Nvwm LLC boosted its position in shares of Danaher by 20.4% in the second quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after purchasing an additional 1,204 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

NYSE DHR opened at $219.31 on Thursday. The stock has a market capitalization of $154.91 billion, a PE ratio of 43.51, a P/E/G ratio of 2.93 and a beta of 0.91. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $242.80. The business has a 50 day simple moving average of $230.07 and a two-hundred day simple moving average of $214.68. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.79 billion. During the same period in the prior year, the company earned $2.14 EPS. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. On average, research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Friday, December 26th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Friday, December 26th. Danaher’s dividend payout ratio is currently 25.40%.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This trade represents a 59.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 30,248 shares of company stock valued at $6,609,663. Insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on DHR. Barclays raised their price objective on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. JPMorgan Chase & Co. boosted their price objective on Danaher from $270.00 to $275.00 and gave the company an “overweight” rating in a research report on Thursday, January 29th. Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 target price (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Guggenheim lifted their target price on Danaher from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Friday, January 2nd. Finally, Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Twenty analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $252.32.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.